Navigation Links
Free DXA Bone Mineral Density and Body Composition in Clinical Trials Webinars to be Held by M2S DXA Division Expert
Date:1/27/2009

M2S Inc., a global provider of image management services for biopharmaceutical and medical device clinical trials, announced today that the company will be holding two free webinars to discuss how state-of-the-art image management can enhance DXA (Dual Energy X-Ray Absorptiometry) quality assurance services for bone mineral density trials and issues to consider in trials using body composition measurements with DXA.

(PRWEB) January 27, 2009 -- M2S Inc., a global provider of image management services for biopharmaceutical and medical device clinical trials, announced today that the company will be holding two free webinars to discuss how state-of-the-art image management can enhance DXA (Dual Energy X-Ray Absorptiometry) quality assurance services for bone mineral density trials and issues to consider in trials using body composition measurements with DXA.

On February 3, 2009 (1:00pm EST), an expert from M2S' DXA Division will present the benefits of electronic image transfer, real-time web-based tracking and processing of DXA bone mineral density images and discuss the potential time and cost savings. The second webinar, to be held February 10 (1:00pm EST), will provide useful information on potential challenges and issues in clinical trials using body composition measurements such as patient positioning, use of phantoms, analysis and outcomes decisions.

DXA (Dual- Energy X-Ray Absorptiometry) is a low-dose (1/10th of traditional x-ray) imaging modality that measures bone mineral density and body mass composition. It is increasingly utilized in clinical trials to assess the safety and effectiveness of drugs under development for osteoporosis, HIV, obesity, oncology, as well as hormonal therapies and pediatric indications.

"These webinars will provide insight and advice on how electronic image transfer can improve the speed and reduce the costs of collecting DXA images in clinical trials and provide useful information for planning trials using body composition," said Reta Rupich, Vice President, M2S DXA division.

To sign up for one or both free webinars, go to our DXA Webinar Sign up Page

About M2S, Inc.:
M2S provides image and data management services for clinical trials sponsors in the biopharmaceutical and medical device industries, patient registry databases and is a recognized leader in 3-D endovascular treatment planning. On December 31, 2008 M2S acquired DXA Resource Group (DRG), a clinical trials service company focused on providing customer-centric, cost-effective quality assurance as well as data and project management for clinical trials involving DXA measurements. For the past 10 years, M2S has managed, under protocol, millions of images from around the globe in various therapeutic areas and in all DICOM modalities. For more information, visit www.m2s.com or www.dxaresourcegroup.com.

###

Read the full story at http://www.prweb.com/releases/electronic/imaging/prweb1917154.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related biology technology :

1. New property found in ancient mineral lodestone
2. Study Finds Widespread Vitamin and Mineral Use Among Cancer Survivors, Although Benefits of Such Use Remain Unclear
3. New insight to demineralization
4. Sea urchin yields a key secret of biomineralization
5. South Africas Minister of Minerals and Energy Welcomes Denham Capital Investment in BioTherm Energy to Develop Power Generation Business
6. deCODE Discovers Common Genetic Variations Contributing to Low Bone Mineral Density and Risk of Osteoporosis
7. AIM Pharmakon (API) Announced a New Proprietary Premium-Quality Natural Concentrated Liquid Calcium and Mineral Supplement Now Available Direct to Consumers
8. 220 Companies Place Switzerland First in Biotech Density Per Capita
9. Genta Receives Notice of Allowances for European Patents Related to Composition and Processes for Tesetaxel, a Leading Oral Taxane
10. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
11. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Free DXA Bone Mineral Density and Body Composition in Clinical Trials Webinars to be Held by M2S DXA Division Expert 
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... A person commits a crime, and the detective ... the criminal down. An outbreak of foodborne illness ... (FDA) uses DNA evidence to track down the bacteria that ... It,s not. The FDA has increasingly used a complex, cutting-edge ... illnesses. Put as simply as possible, whole genome sequencing is ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is pleased ... received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of ... Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform ...
(Date:6/23/2016)... 23, 2016  The Biodesign Challenge (BDC), a university ... to harness living systems and biotechnology, announced its winning ... New York City . ... showcased projects at MoMA,s Celeste Bartos Theater during the ... MoMA,s senior curator of architecture and design, and ...
Breaking Biology Technology:
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
(Date:4/15/2016)... , April 15, 2016 ... the,  "Global Gait Biometrics Market 2016-2020,"  report to ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait biometrics ... of 13.98% during the period 2016-2020. ... angles, which can be used to compute factors ...
(Date:3/29/2016)... LegacyXChange, Inc. (OTC: LEGX ... Protect are pleased to announce our successful effort to ... of writing instruments, ensuring athletes signatures against counterfeiting and ... athletes on LegacyXChange will be assured of ongoing proof ... Bill Bollander , CEO states, "By inserting ...
Breaking Biology News(10 mins):